Erol Fikrig Selected Research

Anaplasmosis

8/2014	Anaplasma phagocytophilum surface protein AipA mediates invasion of mammalian host cells.
10/2012	Ixodes scapularis JAK-STAT pathway regulates tick antimicrobial peptides, thereby controlling the agent of human granulocytic anaplasmosis.
5/2012	Postgenomic analyses reveal development of infectious Anaplasma phagocytophilum during transmission from ticks to mice.
7/2010	Seasonal prevalence of serum antibodies to whole cell and recombinant antigens of Borrelia burgdorferi and Anaplasma phagocytophilum in white-tailed deer in Connecticut.
1/2008	c-Jun NH2-terminal kinase 2 inhibits gamma interferon production during Anaplasma phagocytophilum infection.
8/2007	IL-12/23p40-dependent clearance of Anaplasma phagocytophilum in the murine model of human anaplasmosis.
7/2007	Anaplasma phagocytophilum specifically induces tyrosine phosphorylation of ROCK1 during infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Erol Fikrig Research Topics

Disease

78	Infections 01/2022 - 10/2001
29	Lyme Disease (Disease, Lyme) 02/2022 - 01/2002
19	West Nile Fever 01/2019 - 01/2002
17	Virus Diseases (Viral Diseases) 03/2019 - 09/2003
9	Malaria 01/2022 - 01/2012
8	Zika Virus Infection 01/2021 - 01/2017
8	Encephalitis (Encephalitis, Rasmussen) 12/2013 - 12/2004
7	Bites and Stings (Sting) 01/2021 - 12/2013
7	Anaplasmosis 08/2014 - 07/2007
6	Viremia 11/2020 - 06/2006
5	Dengue (Dengue Fever) 08/2011 - 09/2003
4	Tick-Borne Diseases (Tick-Borne Disease) 01/2022 - 01/2020
4	Tick Bites 12/2021 - 01/2011
4	Communicable Diseases (Infectious Diseases) 11/2021 - 02/2004
4	Ehrlichiosis 01/2005 - 04/2002
3	Human Influenza (Influenza) 08/2021 - 12/2009
3	RNA Virus Infections 01/2021 - 09/2008
3	Bacterial Infections (Bacterial Infection) 01/2017 - 10/2010
2	Syphilis 01/2022 - 08/2002
2	Erythema 12/2021 - 08/2002
2	Arthritis (Polyarthritis) 01/2021 - 06/2002
2	Tick Infestations 01/2020 - 01/2019
2	Coinfection 01/2019 - 11/2005
2	Relapsing Fever 01/2018 - 08/2002
2	Autoimmune Diseases (Autoimmune Disease) 01/2017 - 06/2010
2	Acquired Immunodeficiency Syndrome (AIDS) 05/2015 - 08/2014
2	Starvation 01/2012 - 02/2007
2	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 12/2011 - 10/2004
2	Viral Encephalitis 04/2008 - 01/2004
2	Flavivirus Infections 12/2007 - 12/2005
2	Rheumatoid Arthritis 11/2002 - 08/2002
1	Chikungunya Fever 10/2020

Drug/Important Bio-Agent (IBA)

50	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2002
24	AntibodiesIBA 01/2022 - 10/2001
21	VaccinesIBA 12/2021 - 10/2003
16	AntigensIBA 12/2021 - 10/2001
11	CytokinesIBA 01/2019 - 06/2002
11	Antiviral Agents (Antivirals)IBA 01/2019 - 06/2006
9	Salivary Proteins and PeptidesIBA 12/2021 - 02/2008
7	Messenger RNA (mRNA)IBA 12/2021 - 11/2002
6	InterferonsIBA 01/2021 - 12/2009
6	RNA (Ribonucleic Acid)IBA 11/2020 - 12/2004
6	Lipoproteins (Lipoprotein)IBA 09/2013 - 06/2002
5	Immunoglobulin G (IgG)IBA 08/2021 - 01/2002
5	Immune Sera (Antisera)IBA 01/2021 - 10/2004
4	LipidsIBA 01/2022 - 01/2017
4	Interferon-gamma (Interferon, gamma)IBA 01/2020 - 11/2004
4	Interferon Type IIBA 10/2019 - 03/2008
4	Membrane Proteins (Integral Membrane Proteins)IBA 08/2014 - 01/2002
4	Toll-Like Receptors (Toll-Like Receptor)IBA 06/2010 - 12/2004
4	Immunoglobulin M (IgM)IBA 06/2006 - 01/2002
4	ImmunosorbentsIBA 01/2004 - 01/2002
4	EnzymesIBA 01/2004 - 01/2002
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 03/2014
3	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 02/2007
3	Aluminum Hydroxide (Algeldrate)FDA Link 03/2020 - 06/2005
3	Complement System Proteins (Complement)IBA 01/2019 - 06/2006
3	Interleukin-12 (IL 12)IBA 01/2018 - 08/2007
3	InflammasomesIBA 01/2017 - 05/2009
3	LigandsIBA 11/2012 - 09/2004
3	1-oleoyl-2-stearoylphosphatidylcholineIBA 03/2012 - 01/2004
3	4,5-dibromo-2-pyrrolic acidIBA 03/2012 - 09/2004
3	Phosphotransferases (Kinase)IBA 01/2008 - 06/2002
3	NADPH Oxidases (NAD(P)H oxidase)IBA 11/2005 - 08/2004
2	Adiponectin ReceptorsIBA 02/2022 - 11/2021
2	ChemokinesIBA 01/2021 - 12/2010
2	Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA 03/2019 - 01/2019
2	Small Interfering RNA (siRNA)IBA 04/2018 - 12/2016
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2017 - 07/2007
2	Polysaccharides (Glycans)IBA 01/2017 - 11/2012
2	Peptides (Polypeptides)IBA 01/2017 - 02/2007
2	UbiquitinIBA 01/2016 - 09/2008
2	Antifreeze ProteinsIBA 01/2015 - 10/2014
2	Glycoproteins (Glycoprotein)IBA 01/2015 - 11/2012
2	Antiviral Restriction FactorsIBA 11/2011 - 12/2009
2	Immunosuppressive Agents (Immunosuppressants)IBA 06/2010 - 02/2008
2	Interleukin-8 (Interleukin 8)IBA 06/2010 - 09/2004
2	InterleukinsIBA 02/2009 - 03/2008
2	p38 Mitogen-Activated Protein KinasesIBA 10/2008 - 06/2002
2	Ligases (Synthetase)IBA 09/2008 - 08/2004
2	Immunoglobulins (Immunoglobulin)IBA 12/2007 - 08/2004
2	IronIBA 02/2007 - 09/2005
2	4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA 01/2005 - 07/2002
2	Carrier Proteins (Binding Protein)IBA 09/2004 - 03/2004
2	DecorinIBA 09/2004 - 03/2004
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2022
1	Cardiolipins (Cardiolipin)IBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	NucleosidesIBA 11/2021
1	Adenosine Triphosphatases (ATPase)IBA 01/2021
1	Immunodominant EpitopesIBA 01/2021
1	Chemotactic FactorsIBA 11/2020
1	peptidoglycan recognition proteinIBA 11/2020
1	Scavenger Receptors (Scavenger Receptor)IBA 10/2020
1	Sulfhydryl Compounds (Thiols)IBA 01/2020
1	Oxidoreductases (Dehydrogenase)IBA 01/2020
1	Proto-Oncogene Proteins c-etsIBA 10/2019
1	CaspasesIBA 01/2019

Therapy/Procedure

6	Therapeutics 03/2019 - 12/2005
1	Immunomodulation 12/2021